Nkcfo LLC acquired a new stake in shares of Alpha Teknova, Inc. (NASDAQ:TKNO - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 60,000 shares of the company's stock, valued at approximately $501,000. Nkcfo LLC owned about 0.11% of Alpha Teknova as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TKNO. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Alpha Teknova during the 4th quarter valued at approximately $94,000. Whalen Wealth Management Inc. bought a new position in shares of Alpha Teknova in the fourth quarter worth $240,000. State Street Corp grew its position in shares of Alpha Teknova by 249.3% in the third quarter. State Street Corp now owns 76,645 shares of the company's stock valued at $371,000 after purchasing an additional 54,700 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Alpha Teknova by 24.4% during the 3rd quarter. Geode Capital Management LLC now owns 188,173 shares of the company's stock valued at $911,000 after purchasing an additional 36,914 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in Alpha Teknova during the 3rd quarter worth about $1,483,000. Institutional investors own 13.81% of the company's stock.
Separately, Craig Hallum started coverage on Alpha Teknova in a research report on Monday, February 10th. They set a "buy" rating and a $12.00 price target on the stock.
Get Our Latest Stock Analysis on TKNO
TKNO opened at $8.28 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.94 and a current ratio of 4.73. Alpha Teknova, Inc. has a one year low of $1.15 and a one year high of $10.37. The company has a fifty day moving average price of $8.49 and a 200-day moving average price of $6.60.
Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Alpha Teknova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Teknova wasn't on the list.
While Alpha Teknova currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.